Your browser doesn't support javascript.
loading
Five-Year Outcomes From the United States Pivotal Trial of Valiant Captivia Stent Graft for Blunt Aortic Injury.
Patel, Himanshu J; Azizzadeh, Ali; Matsumoto, Alan H; Velazquez, Omaida C; Rovin, Joshua D; Lombardi, Joseph V; Khoynezhad, Ali; Dai, Yuqing; White, Rodney A.
Afiliación
  • Patel HJ; University of Michigan Frankel Cardiovascular Center, Ann Arbor, Michigan. Electronic address: hjpatel@med.umich.edu.
  • Azizzadeh A; Cedars-Sinai Medical Center, Los Angeles, California.
  • Matsumoto AH; University of Virginia, Charlottesville, Virginia.
  • Velazquez OC; University of Miami Jackson Memorial Hospital, Miami, Florida.
  • Rovin JD; Morton Plant Hospital, Clearwater, Florida.
  • Lombardi JV; Cooper Medical School of Rowan University, Camden, New Jersey.
  • Khoynezhad A; Memorial Care Heart and Vascular Institute, Long Beach, California.
  • Dai Y; Medtronic, Santa Rosa, California.
  • White RA; Memorial Care Heart and Vascular Institute, Long Beach, California.
Ann Thorac Surg ; 110(3): 815-820, 2020 09.
Article en En | MEDLINE | ID: mdl-31991136
BACKGROUND: The Clinical PeRformancE of the Valiant Thoracic Stent Graft with Capitvia Delivery System for the EndovaSCUlar treatment of Blunt Thoracic Aortic Injuries (RESCUE) study evaluating thoracic endovascular repair using the Valiant Captivia endograft for blunt thoracic aortic injury reported promising 30-day outcomes. We now describe 5 years of follow-up of this cohort. METHODS: Fifty patients (mean age 40.7 ± 17.4 years, 76% male, mean injury severity score 38 ± 14.4) were treated for blunt thoracic aortic injury (2010 to 2012) with this endograft. Seventy percent (n = 35) of blunt thoracic aortic injury extent was grade III or higher. Extent of arch repair required full (40%) or partial (18%) left subclavian artery coverage. At 5 years, clinical and imaging compliance was 90.3% (28 of 31) and 67.7% (21 of 31), respectively. RESULTS: Thirty-day mortality was 8%. Three additional patients died of non-device-related causes (respiratory failure, infection, metastatic cancer) through 5-year follow-up, yielding a Kaplan-Meier survival of 85.2% through 5 years. Neither stroke nor spinal cord ischemia was observed at 5 years. Two type II endoleaks seen at 30 days resolved spontaneously, and no additional endoleaks were described in the study cohort through 5 years. No secondary endovascular procedures or conversion to open surgery were reported through 5 years. Four subjects underwent left subclavian revascularization for symptomatic indications. Finally, complete exclusion of the traumatic injury was maintained with no incidences of stent graft kinking, fracture, loss of patency, or migration through 5 years in all patients. CONCLUSIONS: This multicenter clinical trial describes excellent 5-year outcomes and durable exclusion of blunt thoracic aortic injury using a novel stent graft system. Thoracic endovascular repair with this endograft appears to be a safe and effective treatment option for patients with blunt thoracic aortic injury.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Aorta Torácica / Heridas no Penetrantes / Prótesis Vascular / Stents / Implantación de Prótesis Vascular / Lesiones del Sistema Vascular Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Ann Thorac Surg Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Aorta Torácica / Heridas no Penetrantes / Prótesis Vascular / Stents / Implantación de Prótesis Vascular / Lesiones del Sistema Vascular Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Ann Thorac Surg Año: 2020 Tipo del documento: Article